Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.

Fecha de publicación: 01/06/2021 Fecha Ahead of Print: 16/02/2021

Autores de IIS La Fe

Mario Arnao Herraiz

Autor

Participantes ajenos a IIS La Fe

Rodriguez-Otero P
Sirvent M
González-Rodríguez AP
Lavilla E
de Coca AG
Arguiñano JM
Martí JM
Cabañas V
Motlló C
de Cabo E
Encinas C
Murillo I
Hernández-Rivas JÁ
Pérez-Persona E
Casado F
Sampol A
García R
Blanchard MJ
Anguita M
Lafuente AP
Iñigo B
López A
Ribas P
Maldonado R
Bladé J
Mateos MV
Lahuerta JJ
San Miguel JF

Abstract

Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide. Indeed, with currently approved treatments, median progression-free survival (PFS) in the lenalidomide-refractory setting is less than 10 months, reflecting the difficulty in treating this patient population. Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations.

Datos de la publicación

ISSN/ISSNe:: 2152-2650, 2152-2669
Tipo:: Article
Páginas:: 413-420
DOI:: 10.1016/j.clml.2021.02.004
PubMed:: 33741302
Factor de Impacto:: 0,778 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Keywords

Lenalidomide-refractoriness, Pomalidomide, Real-world study, Refractory multiple myeloma, Triplet therapy

Campos de Estudio

Cita

Cita Bibliográfica